Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 3,600 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $325.45, for a total value of $1,171,620.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $42,308.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Stock Up 0.1 %

NASDAQ:UTHR traded up $0.27 during trading hours on Wednesday, hitting $322.23. The company’s stock had a trading volume of 343,222 shares, compared to its average volume of 495,200. The company has a current ratio of 4.35, a quick ratio of 3.64 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $343.98. The stock has a market capitalization of $14.29 billion, a P/E ratio of 15.22, a price-to-earnings-growth ratio of 1.06 and a beta of 0.55. The stock has a fifty day moving average of $310.44 and a 200-day moving average of $263.02.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. During the same quarter in the prior year, the company earned $5.24 EPS. The business’s revenue was up 19.8% on a year-over-year basis. On average, equities analysts forecast that United Therapeutics Co. will post 25.4 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Bank of America cut their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research report on Thursday, August 1st. Oppenheimer boosted their target price on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $310.00 to $321.00 in a research report on Thursday, July 11th. TD Cowen upped their price objective on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Finally, Wells Fargo & Company upped their price objective on United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $331.73.

Hedge Funds Weigh In On United Therapeutics

Several large investors have recently bought and sold shares of UTHR. Norges Bank acquired a new position in United Therapeutics in the fourth quarter valued at $100,519,000. LSV Asset Management boosted its stake in shares of United Therapeutics by 82.5% during the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after buying an additional 436,851 shares during the period. Swedbank AB acquired a new stake in shares of United Therapeutics during the first quarter worth about $97,316,000. Nordea Investment Management AB boosted its stake in shares of United Therapeutics by 677.6% during the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after buying an additional 262,222 shares during the period. Finally, Avidity Partners Management LP purchased a new position in United Therapeutics during the fourth quarter worth about $52,158,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.